1,2,4-benzotriazine-1,4-dioxides
The compound 3-ethyl-6-[3-(4-morpholinyl)propoxy]-1,2,4-benzotriazine 1,4-dioxide and pharmacologically acceptable salts thereof. A method of treating cancer in a subject is also described in which 3-ethyl-6-[3-(4-morpholinyl)propoxy]-1,2,4-benzotriazine 1,4-dioxide or a pharmacologically acceptable salt thereof is administered to tumor cells in a hypoxic environment. Also described is a method of radiosensitising in a subject tumor cells of solid tumors in hypoxic conditions by administering to the subject a pharmaceutical composition containing 3-ethyl-6-[3-(4-morpholinyl)propoxy]-1,2,4-benzotriazine 1,4-dioxide or a pharmacologically acceptable salt thereof in an amount sufficient to produce radiosensitivity in the tumor cells, and subjecting the tumor cells to radiation. A pharmaceutical composition is additionally provided containing a therapeutically effective amount of 3-ethyl-6-[3-(4-morpholinyl)propoxy]-1,2,4-benzotriazine 1,4-dioxide or a pharmacologically acceptable salt thereof and a pharmaceutically acceptable excipient, adjuvant, carrier, buffer or stabiliser.
1. A compound selected from 3-ethyl-6-[3-(4-morpholinyl)propoxy]-1,2,4-benzotriazine 1,4-dioxide and pharmacologically acceptable salts thereof.
2. A method of treating a cancer selected from cervical carcinoma, colon carcinoma and non-small cell lung cancer, comprising the steps of (1) administering a compound as claimed in claim 1 in a therapeutically effective amount to tumour cells in a subject, wherein the tumour cells are in a hypoxic environment, and (2) administering radiotherapy to the tumour cells before, during or after the administration of the compound as defined in claim 1 to the tumour cells.
3. The method as claimed in claim 2 further including the step of administering one or more chemotherapeutic agents to the tumour cells before, during or after the administration of the compound as defined in claim 1 to the tumour cells.
4. The method as claimed in claim 3 wherein the one or more chemotherapeutic agents is selected from Cisplatin or other platinum-based derivatives, Temozolomide or other DNA methylating agents, cyclophosphamide or other DNA alkylating agents, Doxorubicin, mitoxantrone, camptothecin or other topoisomerase inhibitors, Methotrexate, gemcitabine and/or Docetaxel or other taxanes.
5. A method of radiosensitising in a subject tumour cells of solid tumours selected from the group consisting of cervical carcinoma, colon carcinoma and non-small cell lung cancer in hypoxic conditions in vivo, comprising the steps of:
(a) administering to the subject a pharmaceutical composition in an amount sufficient to produce radiosensitivity in the tumour cells, the composition comprising a compound as claimed in claim 1 ; and
(b) subjecting the tumour cells to radiation.
6. A pharmaceutical composition comprising a therapeutically effective amount of a compound as defined in claim 1 and a pharmaceutically acceptable excipient, adjuvant, carrier, buffer or stabiliser.